EGFR
Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma.
Expert Opinion on Drug Delivery 2019 March 27 [Link] Chia PL, Scott AM, John T Abstract Malignant mesothelioma (MM) is an aggressive malignancy arising from the mesothelial cells lining the pleura and other serosal membranes. It is associated with an extremely poor prognosis and has limited therapeutic options. Areas covered: Epidermal growth factor receptor (EGFR)…
Read MoreThe analysis of novel microRNA mimic sequences in cancer cells reveals lack of specificity in stem-loop RT-qPCR-based microRNA detection
BMC Research Notes 2017 November [Link] Winata P, Williams M McGowan E, Nassif N, van Zandwijk N, Reid G Abstract OBJECTIVE: MicroRNAs are frequently downregulated in cancer, and restoring expression has tumour suppressive activity in tumour cells. Our recent phase I clinical trial investigated microRNA-based therapy in patients with malignant pleural mesothelioma. Treatment with TargomiRs,…
Read MoreA link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in Mesothelioma
Molecular Oncology 2017 November 1 [Epub ahead of print] [Link] Schelch K, Kirschner MB, Williams M, Cheng YY, van Zandwijk N, Grusch M, Reid G Abstract Malignant pleural mesothelioma (MPM) is an aggressive malignancy with very limited therapeutic options. Fibroblast growth factor (FGF) signals play important roles in mesothelioma cell growth. Several FGFs and FGF…
Read MoreSafety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
The Lancet. Oncology 2017 September [Epub ahead of print] [Link] van Zandwijk N, Pavlakis N, Kao SC, Linton A, Boyer MJ, Clarke S, Huynh Y, Chrzanowska A, Fulham MJ, Bailey DL, Cooper WA, Kritharides L, Ridley L, Pattison ST, MacDiarmid J, Brahmbhatt H, Reid G Abstract BACKGROUND: TargomiRs are minicells (EnGeneIC Dream Vectors) loaded with…
Read MoreTumor suppressor candidate 2 (TUSC2, FUS-1) and human cancers
Discovery Medicine 2017 May [Link Rimkus T, Sirkisoon S, Harrison A, Lo HW Abstract Tumor suppressor candidate 2 (TUSC2, also known as FUS1) was identified in 2000 as a candidate tumor suppressor gene located in a region on chromosome 3p21.3 that is homozygously deleted in some lung and breast cancers. The deletion is rare in…
Read MorePhase I Trial of Cediranib in combination with cisplatin and pemetrexed in chemo naive patients with unresectable malignant pleural mesothelioma (SWOG S0905)
Journal of Thoracic Oncology 2017 June 6 [Epub ahead of print] [Link] Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K Abstract BACKGROUND: In malignant pleural mesothelioma (MPM), targeting angiogenesis, with cediranib, a vascular endothelial growth factor receptor (VEGFR) and platelet derived growth factor receptor (PDGFR) inhibitor, may…
Read MoreThe inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells
Stem cell research & therapy 2017 May 25 [Link] Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A Abstract BACKGROUND: Malignant pleural mesothelioma is an aggressive cancer, characterized by rapid progression and high mortality. Persistence of tumor-initiating cells (TICs, or cancer stem cells) after…
Read MoreInhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines
Genes & Cancer 2017 January [a href=”https://www.ncbi.nlm.nih.gov/pubmed/28435517″>Link] Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S Abstract Malignant pleural mesothelioma (MPM) is a cancer of the pleural…
Read MoreIntracavitary ‘T4 immunotherapy’ of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells
Cancer Letters 2017 February [Epub ahead of print] [Link] Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J, Maher J Abstract Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but…
Read MoreCommon Fluorescence In Situ Hybridization Applications in Cytology
Archives of Pathology & Laboratory Medicine 2016 August 4 [Epub ahead of print] [Link] Savic S, Bubendorf L Abstract CONTEXT: -Fluorescence in situ hybridization (FISH) is a well-established method for detection of genomic aberrations in diagnostic, prognostic, and predictive marker testing. OBJECTIVE: -To review common applications of FISH in cytology. DATA SOURCES: -The published literature…
Read More